Real-world analysis of brolucizumab in neovascular AMD

被引：0
|
作者：
Rave, Vanessa [1 ,2 ]
Sharma, Kayshaliya [1 ,2 ]
Wagner, Alan [1 ]
Kapoor, Kapil [1 ]
机构：
[1] Wagner & Kapoor Res Inst, Norfolk, VA USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2021年 / 62卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
431
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
    Hoseok Yeom
    Hye Ji Kwon
    Yoon Jeon Kim
    Junyeop Lee
    Young Hee Yoon
    Joo Yong Lee
    [J]. Scientific Reports, 13
  • [22] Dynamics and patterns of recurrence in neovascular AMD during real-world management using automated fluid monitoring
    Prenner, Veronika
    Schmidt-Erfurth, Ursula
    Fuchs, Philipp
    Leingang, Oliver
    Coulibaly, Leonard Mana
    Bogunovic, Hrvoje
    Barthelmes, Daniel
    Reiter, Gregor Sebastian
    [J]. HELIYON, 2024, 10 (10)
  • [23] Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
    Jan Niklas Lüke
    Hamdi Alquoqa
    Ahmad Alsamman
    Bayan Aljabary
    F. Schaub
    L. M. Heindl
    [J]. International Ophthalmology, 2023, 43 : 13 - 25
  • [24] Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry
    Marco A. Zarbin
    Mathew W. MacCumber
    Helene Karcher
    Eser Adiguzel
    Andrew Mayhook
    Andrew LaPrise
    Ver L. Bilano
    Franklin Igwe
    Michael S. Ip
    Charles C. Wykoff
    [J]. Ophthalmology and Therapy, 2024, 13 : 1357 - 1368
  • [25] Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
    Lueke, Jan Niklas
    Alquoqa, Hamdi
    Alsamman, Ahmad
    Aljabary, Bayan
    Schaub, F.
    Heindl, L. M.
    [J]. INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (01) : 13 - 25
  • [26] Correction: Brolucizumab—early real-world experience: BREW study
    Ashish Sharma
    Nilesh Kumar
    Nikulaa Parachuri
    Srinivas R. Sadda
    Giulia Corradetti
    Jeffrey Heier
    Adam T. Chin
    David Boyer
    Pouya Dayani
    Sruthi Arepalli
    Peter Kaiser
    [J]. Eye, 2021, 35 (4) : 1286 - 1286
  • [27] Brolucizumab-early real-world experience: BREW study
    Sharma, Ashish
    Kumar, Nilesh
    Parachuri, Nikulaa
    Sadda, Srinivas R.
    Corradetti, Giulia
    Heier, Jeffrey
    Chin, Adam T.
    Boyer, David
    Dayani, Pouya
    Arepalli, Sruthi
    Kaiser, Peter
    [J]. EYE, 2021, 35 (04) : 1045 - 1047
  • [28] The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
    Pearce, Ian
    Amoaku, Winfried
    Bailey, Clare
    Downey, Louise
    Gale, Richard
    Ghanchi, Faruque
    Hamilton, Robin
    Mahmood, Sajjad
    Menon, Geeta
    Nosek, Jenny
    Talks, James
    Yang, Yit
    [J]. EYE, 2022, 36 (09) : 1725 - 1734
  • [29] Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
    Ramin Khoramnia
    Marta S. Figueroa
    Lars-Olof Hattenbach
    Carlos E. Pavesio
    Majid Anderesi
    Robert Schmouder
    Yu Chen
    Marc D. de Smet
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1843 - 1856
  • [30] The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
    Ian Pearce
    Winfried Amoaku
    Clare Bailey
    Louise Downey
    Richard Gale
    Faruque Ghanchi
    Robin Hamilton
    Sajjad Mahmood
    Geeta Menon
    Jenny Nosek
    James Talks
    Yit Yang
    [J]. Eye, 2022, 36 : 1725 - 1734
12345